Overview
UBS has identified a group of European companies it classifies as "European Leaders," selecting them for inclusion on its Global Equity Focus List. According to UBS, the list comprises the bank's highest-conviction equity ideas, chosen on the basis of fundamentals, valuation and long-term growth potential. Collectively, UBS says these names embody Europe’s competitive strengths across technology, healthcare, industrials and the energy transition.
Why these companies were chosen
UBS frames the selection around several large-scale structural forces: AI and automation, decarbonization, infrastructure investment, demographic change and financial-sector reform. The bank views the nominated firms as positioned to benefit from those trends because of their market roles, product sets and strategic exposure to the underlying themes.
Companies named as European Leaders
ASML - Described by UBS as a cornerstone of the global semiconductor ecosystem, ASML is noted for supplying advanced lithography machines essential to chip manufacturing. UBS highlights ASML’s near-monopoly in EUV technology and characterizes the company as indispensable to growth in AI and high-performance computing. The bank points to strong pricing power and long-term demand visibility as reasons ASML is a structural winner.
Siemens - UBS highlights Siemens’ exposure to industrial automation, digitalization and smart infrastructure. The company’s activities in factory automation and digital industries are seen to align with the Industry 4.0 theme, and UBS positions Siemens as an enabler of productivity improvements across manufacturing sectors.
Schneider Electric - Positioned at the intersection of electrification and digital energy management, Schneider Electric’s solutions are credited with improving energy efficiency across industries and buildings. UBS views the company as playing a critical role within both automation and decarbonization themes.
AstraZeneca - UBS points to AstraZeneca’s pipeline strength in oncology and biopharmaceuticals. The firm’s innovation-led growth and global scale are cited as reasons it should benefit from rising healthcare demand associated with aging populations.
Novartis - Seen as a defensive growth stock by UBS, Novartis is described as having a focused pharmaceuticals portfolio with notable exposure to innovative therapies. UBS notes consistent cash flows and strategic restructuring toward higher-margin drugs as supporting its view.
Banco Santander - UBS includes Banco Santander as a play on trends toward financial-sector normalization and reform. The bank highlights Santander’s benefit from higher interest rates and improving margins as well as its geographic diversification across Europe and emerging markets.
Iberdrola - Characterized as a global leader in renewable power generation, Iberdrola is noted for significant investments in wind and grid infrastructure. UBS positions the company as a core beneficiary of Europe’s transition to clean energy.
Air Liquide - UBS points to Air Liquide’s role in the hydrogen economy and industrial decarbonization. The company’s stable business model and exposure to energy-transition technologies are cited as supporting long-term growth prospects.
Prysmian - Identified for its supply of essential cable infrastructure for electricity transmission, Prysmian is highlighted for its role in grid expansion and renewable integration, making it a direct beneficiary of electrification efforts.
Heidelberg Materials - UBS describes Heidelberg Materials as transitioning toward low-carbon cement and sustainable construction solutions. The bank sees the company as positioned to benefit from infrastructure investment and green building initiatives.
Contextual note
UBS groups these names under the banner of "European Leaders" to indicate their exposure to the specific structural themes the bank deems most consequential. The Global Equity Focus List is presented as the bank’s concentrated set of highest-conviction equity ideas, based on a mix of fundamentals, valuation and anticipated long-term growth.